Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study

Overview of attention for article published in Frontiers in immunology, November 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Evaluation of the effectiveness and safety of combining PD-1/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Article in Frontiers in Immunology (September 2024)

Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study

Article in Neoplasia (September 2024)

Programmed death-1 inhibitors as treatment for other subtypes of lymphomas not recommended in the guidelines: Real-world data from a single center in China

Preprint in Research Square (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.